Case of the month: Rivastigmine (Exelon®) toxicity with evidence of respiratory depression

Emergency Medicine Journal

Volumn 23, Issue 1, 2006, Pages 82-83

  Sener, S ^a   Ozsarac, M ^b  

^a Akay Hospital   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ATROPINE; CHOLINESTERASE INHIBITOR; GALANTAMINE; METOCLOPRAMIDE; ONDANSETRON; PRALIDOXIME; RIVASTIGMINE; TACRINE;

ADULT; ARTICLE; BRADYCARDIA; CASE REPORT; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG INTOXICATION; DRUG OVERDOSE; EMERGENCY WARD; HUMAN; HYPERSALIVATION; INTENSIVE CARE UNIT; MALE; NAUSEA; PRIORITY JOURNAL; RESPIRATION DEPRESSION; STOMACH LAVAGE; SUICIDE ATTEMPT; VOMITING;

ADULT; CHOLINESTERASE INHIBITORS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; RESPIRATORY INSUFFICIENCY; SUICIDE, ATTEMPTED;

EID: 30344471506     PISSN: 14720205     EISSN: None     Source Type: Journal    
DOI: 10.1136/emj.2004.017301     Document Type: Article

References (13)

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
2. Raskind M, Kumar V, Malaty L, et al. Rivastigmine for Alzheimer's disease: improvement versus reduced worsening. Prim Care Companion J Clin Psychiatry 2000;2:134-8.
3. Bonner LT, Peskind ER, Pharmacological treatments of dementia. Med Clin North Am 2002;8:657-74.
4. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylacetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998;97:244-50.
5. Enz A, Boddeke H, Gray J, et al. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylacetylcholinesterase inhibitor. Ann N Y Acad Sci 1991;640:272-5.
6. Doggrell SA, Evans S. Treatment of dementia with neurotransmission modulation. Expert Opin Investig Drugs 2003;12:1633-54.
7. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
8. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992;327:1253-9.
9. Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylacetylcholinesterase inhibitor, in patients with mild to slightly severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
10. Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylacetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 1999;19:513-21.
11. Polinsky PJ. Clinical pharmacology of rivastigmine: a new-generation acetylacetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47.
12. Ellenhorn MJ. Organophosphates. In: Ellenhorn's medical toxicology. London: Lippincott Williams Wilkins, 1997:1614-21.
13. US Food and Drug Association. Exelon® (rivastigmine tartrate) capsules. www.fda.gov/cder/foi/label/2000/20823lbl.pdf. Accessed 31 May, 2004.